2022年4月28日 · 抗体偶联药物 （ Antibody-drug conjugates，ADC ）是一类融合了抗体与小分子细胞毒素两种组分的新兴药物。其中抗体提供细胞靶向性，可以将药物比较精准的输送到靶细胞，最大限度地减少对正常组织细胞的毒性，因此在肿瘤治疗以其他领域如免疫、抗感染等都具有 ...

2023年6月29日 · ADCs are a hybrid construct combining, via chemical conjugation, biologic (monoclonal antibody) and small-molecule (drug-linker) moieties into a single drug substance. They also present significant technical and strategic challenges for …

Linker-drug (LD) 与抗体的偶联是产生ADC和确定ADC关键质量属性的关键步骤，其可以从根本上改变ADC的药代动力学和治疗指数。 目前超过95%的ADC基于两种偶联技术：半胱氨酸烷基化或赖氨酸酰化。

2023年7月27日 · 抗体药物偶联物 (ADC)作为新兴的抗癌治疗药物，可以将高细胞毒性分子直接递送至癌细胞发挥杀伤作用。 ADC是由单克隆抗体通过Linker与细胞毒性化学物质 (Payload)共价结合，Linker在ADC治疗效果中发挥着关键作用，其特性极大地影响ADC的治疗指数、药效学和药代动力学。 为了使ADC具有选择性和疗效，所采用的Linker应努力实现三个关键特性[1]： (1)循环稳定性高：在Payload到达靶点之前不会释放Payload，从而将脱靶效应降到最低； (2)高水溶 …

2021年12月1日 · Antibody–drug conjugate (ADC), comprising a monoclonal antibody (mAb), the cytotoxic payload and the linker, has developed rapidly in recent years and is gradually revolutionizing clinical cancer therapy.

抗体偶联药物（Antibody Drug Conjugates，ADC）是一类新型强效抗肿瘤药物，结合了抗体的靶向能力和细胞毒药物的杀伤效应，在肿瘤治疗领域展现出了优秀的疗效和潜力。

2024年9月30日 · Antibody-drug conjugates (ADCs) are “biological bullets” that combine cytotoxic drugs (payloads) with antibodies through “linkers.” ADCs consist of five key elements: target, antibody, linker, payload, and conjugation method.

2 天之前 · In recent years, drug conjugates have emerged as a promising targeted delivery system [].They typically consist of a targeting carrier, a linker, and a payload and are designed to deliver the toxic payload directly to cancer cells (Fig. 1B). This strategy has successfully enhanced the therapeutic efficacy of cytotoxic drugs while reducing their toxic side effects [].

2 天之前 · Antibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker ...

2 天之前 · OBI-992 is an investigational ADC composed of a novel TROP2 antibody (R4702) conjugated with exatecan through a hydrophilic enzyme-cleavable peptide linker (the structure was revealed in previous ...